舒泰神BDB-001注射液(ANCA相关性血管炎适应症)获I/II期临床研究总结报告

Core Viewpoint - The company has received a summary report on the I/II phase clinical study of BDB-001 injection for ANCA-associated vasculitis (AAV), indicating promising disease control and good safety tolerance [1] Group 1 - The I/II phase clinical trial of BDB-001 has shown good efficacy in controlling disease remission [1] - The safety and tolerability of BDB-001 have been reported as favorable [1] - The company plans to actively advance to the III phase clinical trial to further validate the clinical benefits for AAV patients [1]